AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15310345
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of inhaled medical air and titrated intravenous midazolam
Trial: 15310345
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of inhaled 40% nitrous oxide in oxygen and titrated intravenous midazolam
Trial: 15310345
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of inhaled mixture of sevoflurane 0.3% and nitrous oxide 40% in oxygen with titrated intravenous midazolam
Trial: 12796591
Drug: Daily schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily schedule of topotecan (1.5 mg/m2 daily for 5 days every 3 weeks)
Trial: 12796591
Drug: Continuous-infusion schedule
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion schedule of topotecan (1.3 mg/m2 per day over 72 hours every 4 weeks)
Trial: 10479878
Drug: Usnic acid
RxNorm normalized name: Usnic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally before and after RS (n = 25)
Trial: 10479878
Drug: Usnic acid
RxNorm normalized name: Usnic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally after RS (n = 25)
Trial: 10479878
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no therapy after RS) (n = 50)
Trial: 10479878
Drug: Usnic acid
RxNorm normalized name: Usnic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally (both before and after RS)
Trial: 8753634
Drug: Concurrent group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent group (n = 456)
Trial: 8753634
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (ED, concurrent, preprogram control)
Trial: 1888047
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine with 0.1 mEq sodium bicarbonate added to each 20 ml (n = 30)
Trial: 4003494
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin 1%
Trial: 26037728
Drug: Lactoferrin 250
RxNorm normalized name: lactoferrin 250 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin 250 mg capsules once daily for eight consecutive weeks
Trial: 26037728
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate 150 mg capsules once daily for eight consecutive weeks
Trial: 25078310
Drug: Alemtuzumab-based treatment
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab-based treatment (alemtuzumab followed by low-dose tacrolimus and mycophenolate without steroids)
Trial: 25078310
Drug: Basiliximab-based treatment
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab-based treatment (basiliximab followed by standard-dose tacrolimus, mycophenolate, and prednisolone)
Trial: 25078310
Drug: Alemtuzumab-based treatment
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab-based treatment
Trial: 25078310
Drug: Basiliximab-based treatment
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Basiliximab-based treatment
Trial: 19933534
Drug: Perioperative steroid
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative steroid therapy
Trial: 22832429
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment for 8 weeks
Trial: 30506623
Drug: Tacrolimus (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (3 formulations, each for two 1-week periods)
Trial: 26892001
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) coupled with Virtual Reality Exposure Therapy (VRET)
Trial: 22395336
Drug: Dabigatran (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (150 mg twice a day)
Trial: 11880018
Drug: Rapid induction
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid induction with 2.0 mg/kg propofol followed by P5
Trial: 2509250
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (LA) depot treatment, 3.75 mg IM every 4 weeks for 12 weeks (group A)
Trial: 2509250
Drug: Placebo IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IM injection every 4 weeks for 12 weeks (group B)
Trial: 2509250
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (LA) depot treatment, 3.75 mg IM every 4 weeks for 12 weeks (group A) in patients with large uteri
Trial: 2509250
Drug: Placebo IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IM injection every 4 weeks for 12 weeks (group B) in patients with large uteri
Trial: 28720281
Drug: H9N2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H9N2 vaccine with AS03 adjuvant (1.9µgHA+AS03A, 1.9µgHA+AS03B, 3.75µgHA+AS03A, 3.75µgHA+AS03B)
Trial: 28720281
Drug: H9N2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H9N2 vaccine without adjuvant (15µg HA)
Trial: 28720281
Drug: H9N2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H9N2 vaccine (any formulation) administered a third dose on day 182
Trial: 25673443
Drug: Tripterygium wilfordii
RxNorm normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripterygium wilfordii Hook F (TwHF) 20 mg, 3 times a day for 8 weeks
Trial: 25673443
Drug: Acitretin 30
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acitretin 30 mg, once a day for 8 weeks
Trial: 3318436
Drug: Nabumetone (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone (1,000 mg taken at bedtime)
Trial: 31900091
Drug: Isotonic exercises
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic exercises and relaxing techniques, performed twice a week for one month.
Trial: 28974425
Drug: Liposomal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal spray (n=28)
Trial: 28974425
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no MG dropout)
Trial: 17394002
Drug: Household common
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household common salt solution (10 g NaCl in 1 l tap water)
Trial: 11952881
Drug: Multiple Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple Insulin Injection (MI) therapy for 9 weeks
Trial: 11952881
Drug: Bedtime Insulin
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime Insulin (BTI)
Trial: 2694492
Drug: Tensilon (edrophonium)
RxNorm normalized name: edrophonium chloride Injectable Solution [Tensilon]
DrugBank: Edrophonium (DB01010)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tensilon (edrophonium) administered at 2 hours
Trial: 2694492
Drug: Philippine cobra
RxNorm normalized name: Viola philippica whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Philippine cobra antivenom (20, 50 or 100 ml) administered by constant intravenous infusion over 30 min
Trial: 412611
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (prior inhalation)
Trial: 31961936
Drug: Intermittent enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent enteral feedings 5 times daily at 4-hour intervals
Trial: 31961936
Drug: Intermittent enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent enteral feedings 10 times daily at 2-hour intervals
Trial: 28602319
Drug: OMS302 (Omidria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMS302 (Omidria [phenylephrine and ketorolac injection 1.0%/0.3%])
Trial: 28602319
Drug: Vehicle (balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (balanced salt solution)
Trial: 19828955
Drug: Oral mesalazine
RxNorm normalized name: mesalamine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mesalazine (4 g) + topical mesalazine enema (1 g)
Trial: 19828955
Drug: Oral mesalazine
RxNorm normalized name: mesalamine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mesalazine (4 g) alone
Trial: 17006600
Drug: L-methionine (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-methionine (active treatment)
Trial: 2557304
Drug: TRT (Thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRT (Thoracic Radiation Therapy)
Trial: 31781699
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded implants with provisional resin fixed partial denture
Trial: 31781699
Drug: Conventionally loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally loaded implants according to the one-stage unloaded protocol
Trial: 25966791
Drug: Balugrastim 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balugrastim 30 mg
Trial: 24485296
Drug: Balugrastim 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balugrastim 40 mg
Trial: 25966791
Drug: Balugrastim 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balugrastim 50 mg
Trial: 15333415
Drug: oxycodone/acetaminophen 10/650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxycodone/acetaminophen 10/650 mg
Trial: 11117368
Drug: RS‐127445 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS‐127445 (500 mg)
Trial: 9122731
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon alpha (rIFN‐alpha) as a single agent
Trial: 9122731
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rIFN‐alpha with recombinant interleukin‐2 (rIL‐2)
Trial: 9122731
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rIFN‐alpha with combination chemotherapy regimens
Trial: 9122731
Drug: Chemoimmunotherapy using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotherapy using dual biologic agents
Trial: 26156797
Drug: LNS (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNS (140 g/d)
Trial: 21674263
Drug: New formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulations of ziprasidone (inclusion complex with cyclodextrin, nano-suspension, semi-ordered HCl in polymer matrix)
Trial: 21674263
Drug: New formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New formulations of ziprasidone
Trial: 21674263
Drug: Commercial capsules
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial capsules (Geodon®) dosed in the fed state
Trial: 18551084
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17beta-estradiol and 2 mg drospirenone (DRSP)
Trial: 19479398
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with paclitaxel (200 mg/m²) and carboplatin (AUC 6) for 3 cycles (q21)
Trial: 19479398
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with paclitaxel and carboplatin
Trial: 8245523
Drug: 12.5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 micrograms of rgp160-mam vaccine
Trial: 8245523
Drug: 50.0 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50.0 micrograms of rgp160-mam vaccine
Trial: 8245523
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms of rgp160-mam vaccine (boosted at 18 months)
Trial: 30142768
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and IVF‐ET combined treatment group
Trial: 30142768
Drug: IVF‐ET single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF‐ET single treatment group
Trial: 23057533
Drug: Injection lipolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection lipolysis and hyaluronic acid dermal filler
Trial: 23057533
Drug: Injection lipolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection lipolysis and hyaluronic acid dermal filler + non-ablative 1540 fractional laser
Trial: 21411505
Drug: Ginseng root
RxNorm normalized name: ginseng root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng root extract (8 g/day)
Trial: 21411505
Drug: Ginsenoside Re
RxNorm normalized name: Ginsenoside Re
DrugBank: Ginsenoside B2 (DB14815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginsenoside Re (250‐500 mg/day)
Trial: 12813332
Drug: UFH-IPC (unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH-IPC (unfractionated heparin plus intermittent pneumatic compression)
Trial: 9359537
Drug: Atorvastatin (aggressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (aggressive lipid-lowering therapy)
Trial: 1731548
Drug: Rapid administration
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid administration of midazolam (0.1 mg/kg IV over 15 s)
Trial: 1731548
Drug: Slow administration
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow administration of midazolam (0.1 mg/kg IV over 5 min)
Trial: 6608846
Drug: Amiodarone (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (1500 mg/24 hours IV + 200 mg orally every 8th hour for 3 days, then 200 mg orally 3 times daily)
Trial: 6608846
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg every 6th hour)
Trial: 26471807
Drug: i-gel airway
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel airway (IGA)
Trial: 17343554
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) at a dosage of 0.25 mg/kg
Trial: 16623024
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera cream applied 30 minutes before, immediately after, or both before and after UV exposure
Trial: 7426527
Drug: Omnopon by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omnopon by intramuscular injection for 24 hours after operation
Trial: 7426527
Drug: Salbutamol by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol by intravenous infusion
Trial: 9226208
Drug: Liothyronine (L-T3)
RxNorm normalized name: L-T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liothyronine (L-T3)
Trial: 31271045
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy with adjustment of the challenge-skill balance
Trial: 26233871
Drug: Onion peel
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onion peel extract (OPE) 100mg quercetin/d, 50mg quercetin twice daily; n=36 participants
Trial: 19143950
Drug: 2 mcg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mcg.kg(‐1) IV fentanyl
Trial: 19143950
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine gel applied over the cornea of the operative eye
Trial: 18342502
Drug: Intensive acute
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive acute lymphoblastic leukaemia type chemotherapy regimen without irradiation
Trial: 15386806
Drug: Rosiglitazone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone plus insulin (insulin + RSG group)
Trial: 15386806
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin alone (insulin group)
Trial: 16943394
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg twice daily
Trial: 414266
Drug: Imipramine -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine - 25 mg t.d.s.
Trial: 414266
Drug: Viloxazine -
RxNorm normalized name: viloxazine
DrugBank: Viloxazine (DB09185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Viloxazine - 50 mg t.d.s.
Trial: 414266
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - no tablets
Trial: 31742891
Drug: Lower BP
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower BP treatment targets (not specifically defined)
Trial: 23153515
Drug: Multifaceted ergonomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted ergonomic intervention program (8-week duration including ergonomic training, daily exercise program, equipment modification, computer workstation assessment, typing training)
Trial: 16556618
Drug: Antioxidant supplements
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplements (beta carotene and vitamins C and E)
Trial: 11007223
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg intravenously over 20 min, followed by 100 mg over the next 40 min)
Trial: 8788536
Drug: Caffeine (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3.3 mg/kg, equivalent to 2-3 cups of coffee)
Trial: 1632541
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose infusion of 0.125% bupivacaine at 6 mL/h after a 3-in-1 nerve block with 30 mL of 0.25% bupivacaine
Trial: 1632541
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional intramuscularly administered narcotics)
Trial: 22974129
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (OMT) only
Trial: 25427182
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing with adjunctive laser therapy (5W), n=28
Trial: 16036208
Drug: Alcohol consumption
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption (0.7 g/kg for males and 0.6 g/kg for females)
Trial: 9160036
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (S)
Trial: 30099096
Drug: Daily nitrate
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily nitrate supplementation (70 mL beetroot juice, n = 20)
Trial: 30099096
Drug: Placebo (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (70 mL nitrate-depleted beetroot juice, n = 20)
Trial: 16631281
Drug: None (no-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None (no-treatment control group)
Trial: 12727080
Drug: Azithromycin 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 4.5 g total for 3 weeks (1 x 500 mg weekly for 3 days)
Trial: 12420857
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg b.i.d. for 15 days
Trial: 1978480
Drug: Remoxipride 50
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride 50 mg single dose
Trial: 1978480
Drug: Remoxipride 50
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride 50 mg, 100 mg, and 200 mg twice daily
Trial: 349155
Drug: Rubidium chloride;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubidium chloride; dosage not specified; duration not specified